Clinical Trial Update: A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor [Phase 1]

View source ↗

Summary

Phase 1 study evaluating whether BI 907828 exposure in people with advanced cancer is affected by coadministration of an OATP inhibitor or a CYP3A inhibitor; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• BI 907828

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Solid Tumors | Phase 1 | Status: COMPLETED